Executive Vice President and Chief Corporate Affairs Officer, Sally Susman, is leaving after serving the company for 18 long ...

Pfizer chief corporate affairs officer Sally Susman is departing the company after roughly two decades, CEO Albert Bourla ...

"Pfizer CEO Albert Burla (sic) is stepping down and now says the mRNA technology was not sufficiently proven when launched," reads the caption of a Dec. 10 Facebook clip (direct link, archived link).

Pfizer CEO Albert Bourla inflicts injury on his company — and all of pharma. The hiring of a former top FDA official amplifies ‘revolving door’ criticism at the worst possible time.

In a difficult year for Pfizer, in which its share price fell by 44%, CEO Albert Bourla’s compensation fell by 35%, from $33M to $21.6M in 2023.

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement ...

A clip of an old interview showing Pfizer CEO Albert Bourla talking about the U.S. Food and Drug Administration’s approval of the company’s COVID-19 vaccine is circulating on social media.

Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the pharmaceutical giant's struggling share price and refine its strategic ...

When a novel coronavirus struck in early 2020, Pfizer’sPFE0.24%increase; green up pointing triangle chief executive, Dr. Albert Bourla, saw an opportunity to help save the world. He pushed the ...

In today’s CEO Daily: Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: Trump’s tariff regime is open to compromises.

Pfizer reaffirmed $10–$15 billion for business development, with focus on immunology and cardiometabolic expansion. CEO Bourla says national security concerns are central to U.S. drug ...